India, Aug. 14 -- Aurobindo Pharma on Friday said that the US Food and Drug Administration (USFDA) has issued a warning letter to a formulation manufacturing facility of its subsidiary, Eugia Pharma Specialities Ltd, in Telangana.
The development follows a USFDA inspection of Eugia Pharma's Unit-I facility conducted between February 16 and February 27, 2026. The inspection concluded with four observations, following which the regulator classified the facility under 'Official Action Indicated' (OAI) status.
The warning letter relates to regulatory observations identified during the inspection of the Telangana-based formulation manufacturing facility.
Published by HT Digital Content Services with permission from Dion Global Solutions Limit...